2020 Year in Review - Non–Small-Cell Lung Cancer

Skip to main content

Lung Cancer

Poziotinib Shows Promise for Treating Patients with NSCLC and EGFR or HER2 Exon 20 Insertion Mutations

Lung Cancer

Savolitinib Shows Potential for Patients with NSCLC and MET Exon 14 Skipping Mutations

Lung Cancer

FLAURA Trial: Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Lung Cancer

ALEX Trial: Alectinib versus Crizotinib in Treatment-Naïve Advanced ALK-Positive NSCLC

Lung Cancer, VEGF Inhibitors

Inhibition of VEGFR and EGFR with Apatinib + Gefitinib as First-Line Therapy Increased Progression-Free Survival

Lung Cancer

Patritumab Deruxtecan Shows Promise in Treating Patients with EGFR-Mutated NSCLC

Lung Cancer

Bevacizumab + Osimertinib Did Not Increase Progression-Free Survival versus Osimertinib Alone in Patients with Advanced Adenocarcinoma and EGFR T790M Mutations

Lung Cancer

Lower Dose of Afatinib Shows Promising Clinical Efficacy in Patients with NSCLC and EGFR Mutation

Tepotinib in NSCLC with MET Exon 14 Skipping Mutation (VISION Study)

Lung Cancer

ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC

1
2
3

Page 3 of 3
Results 21 - 30 of 30